A provocative conversation to spark positive change in cancer health disparities, patient access and cancer health outcomes.
On Wednesday, June 15 we gathered for our annual summit, Disrupting the System, where we tackle the obstacles cancer patients face in clinical trial participation and explore real solutions.
* New this year, a special ‘Fireside Chat’ segment featuring Senator Bob Menendez (D-NJ), co-author of the DIVERSE Trials Act.
Watch the Recording Here (fast forward to 18:00 Minutes):
View the Disrupting the System V Summary HERE
Panel 1 Info & Panelists
Did you know when people are diagnosed with cancer, their ability to access treatment and surgeries more often comes down to the type of insurance they have? We’ll talk about how often this happens, what it means for patients and most importantly – what can be done to change it.
Dana Dornsife, Founder and Chief Mission and Strategy Officer, Lazarex Cancer Foundation, moderates this panel.
- Sharrelle Barber, ScD, MPH , Drexel University
- Jane Garcia, CEO, Clínica de la Raza
- Richard N. Gottfried, New York State Assembly Member
- Jeanne Regnante, Strategic Health Equity Advisor, Tigerlily Foundation and President, Patient 3i, LLC
Panel 2 Info & Panelists
Did you know the FDA doesn’t mandate reporting of race and ethnicity in clinical trials? Lack of participant data results in the absence of information on risks and side effects for patients of color – even for treatment of cancers that predominantly affect patients of color. We’ll dig into what’s happening now and what can be done to ensure that all drugs are safe, effective and equitable .
Stephanie Rivera, CEO, Lazarex Cancer Foundation, moderates this panel.
- Danielle Carnival, PhD, White House Cancer Moonshot Coordinator
- Rhonda Long, Cancer survivor, Lazarex client
- Alicia Staley, VP Patient Engagement, Medidata
- Dr. Marya Shegog, PhD, MPH, Health Equity & Diversity Director, Lazarex Cancer Foundation
The Disruptor Award
This year’s Disruptor Awardees go to two individuals who are working tirelessly to improve access to cancer care and cancer health outcomes.
- Senator Bob Menendez (D-NJ), co-author of the DIVERSE Trials Act
- Freddie Muse Jr., Founder and CEO, The Men’s Cancer Network
Special Fireside Chat
U.S. Senators Bob Menendez (D-N.J.), the highest-ranking Latino in Congress, and Tim Scott (R-S.C.) introduced bipartisan, bicameral legislation to improve access to and diversity in clinical drug and treatment trials.
Senator Menendez will talk about the DIVERSE Trials Act and his efforts to ensure more patients, regardless of economic means or geographic location, can access the best treatment options available without having to bear additional costs or inconveniences.
About Disrupting the System
Disrupting the System is an annual summit hosted by Lazarex Cancer Foundation to provide a platform for provocative and constructive dialogue to lead to positive change in the fight against cancer and cancer health disparities. The event brings together disruptors, innovators and change-makers in oncology and patient advocacy all united in one goal: to identify opportunities to tackle the tough issues and take action to support equitable patient access, improve cancer health disparities, and achieve better cancer health outcomes for ALL.
Medidata is leading the digital transformation of life sciences, creating hope for millions of patients. Medidata helps generate the evidence and insights to help pharmaceutical, biotech, medical device and diagnostics companies, and academic researchers accelerate value, minimize risk, and optimize outcomes. More than one million registered users across 1,700+ customers and partners access the world’s most-used platform for clinical development, commercial, and real-world data. Medidata, a Dassault Systèmes company, is headquartered in New York City and has offices around the world to meet the needs of its customers. Discover more at www.medidata.com and follow us @Medidata.